FDA Authorizes Increased Storage Time of Thawed Pfizer/BioNTech COVID-19 Vaccine
The agency is authorizing extending the time undiluted, thawed vaccine vials can be stored in the refrigerator to one month.
FDA announced on May 19, 2021 that it was authorizing extending the time undiluted, thawed Pfizer/BioNTech COVID-19 vaccine vials can be stored in the refrigerator at 2 0C to 8 0C to one month. The change comes after the agency reviewed data submitted by Pfizer that demonstrated vials of the vaccine remained stable for up to one month at refrigerator temperatures. Thawed, undiluted vaccine vials were previously stored in the refrigerator for up to five days. The European Medicines Agency also approved the extended refrigeration time period.
“Making COVID-19 vaccines widely available is key to getting people vaccinated and bringing the pandemic to an end. Pfizer Inc. submitted data to the FDA to support storage of undiluted, thawed vials of its COVID-19 vaccine for up to one month at refrigerator temperatures. This change should make this vaccine more widely available to the American public by facilitating the ability of vaccine providers, such as community doctors’ offices, to receive, store, and administer the vaccine,” said the Center for Biologics Evaluation and Research, Peter Marks, MD, PhD, in a press release.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
